Inclusion Criteria:

Disease Characteristics

• The patient must be 18 years of age or older.
• The patient must have squamous cell carcinoma of the head and neck.
• The squamous cell carcinoma must be Ep-CAM positive.
• ECOG performance status of 0, 1, 2 or 3.
• 12 week life expectancy

Prior/Concurrent Therapy

• The patient must have received therapy for their primary disease (eg, surgery and/or radiotherapy, chemo-radiotherapy or chemotherapy).
• The patient must have been diagnosed with persistent or recurrent disease or a second primary tumour.
• The patient's disease must be refractory.
• There must be at least 2 weeks between the last dose of chemotherapy or radiotherapy and receiving study drug or 4 weeks between the last dose of an experimental drug and receiving study drug.

Patient Characteristics

• The patient must have adequate hepatic function [alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × upper limit of normal (ULN) and bilirubin level ≤1.5 × ULN].
• The patient must have adequate renal function (serum creatinine < 1.5 × ULN).
• The patient must have the following hematological values: granulocytes ≥1500/μL, platelets ≥75 000/μL and hemoglobin >8 g/dL.
• The patient must have prothrombin time and partial thromboplastin time within normal limits.

Other

• Women of childbearing potential and male patients must agree to use a highly effective contraceptive method.

Exclusion Criteria:

• The patient has clinically significant distant metastases.
• The patient is eligible to have surgical resection or radiotherapy, chemo-radiotherapy or chemotherapy.
• The patient has a nasopharyngeal tumour.
• The patient has AIDS, hepatitis C or hepatitis B.
• The patient has clinically significant renal or hepatic disease.
• Tumors are prone to bleeding.
• The patient is pregnant or lactating.
• The patient requires 'blood thinning' medications and can not safely discontinue the medication.
• The patient is currently enrolled in another clinical trial.